Seattle Genetics has entered into a collaboration agreement with GlaxoSmithKline under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology, with multiple antigens to be named by GSK. “By collaborating with leading companies such as GSK, we are broadening the reach of our proprietary ADC technology while also generating substantial non-dilutive capital for Seattle Genetics,” said Eric L. Dobmeier, chief business offi...